Aptevo Therapeutics Inc. (APVO) Key Metrics
APVO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.9M
- Enterprise value
- −$2.2M
- P/E (TTM)
- 0.0
- Forward P/E
- 3.9
- PEG ratio
- —
- Price / sales
- 2.7
- Price / book
- 0.6
- EV / EBITDA
- 0.4
- Dividend yield
- —
- Beta
- 1.68
APVO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAPVO returns How much profit the business earns on the capital it uses.
APVO financial health Debt, liquidity and how easily interest is covered.
APVO efficiency & capital use Working capital cycle and where the cash goes.
APVO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
APVO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
APVO cash returned to shareholders
APVO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $9.43 | $1,551.60 | $106,080.48 | $1,359,705.60 | $4,612,449.60 | $21,479,832.00 | $5,370,251.04 | $10,420,502.40 | $34,789,708.80 | $20,020,492.80 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −234.6% | −284.3% | −115.3% | 83.7% | −306.7% | −124.8% | −211.6% | −95.5% | 10.5% | −161.5% |
| Return on invested capital (ROIC) | — | — | −816.5% | — | — | −163.2% | −155.5% | −207.4% | −245.4% | −192.9% |
| Return on assets (ROA) | −121.4% | −119.4% | −59.0% | 17.7% | −49.6% | −33.2% | −73.9% | −58.2% | 6.7% | −110.0% |
| Return on tangible assets | −95.5% | −154.8% | −70.1% | 23.5% | −48.3% | −33.1% | −91.2% | −86.3% | 6.3% | −145.4% |
| Free cash flow margin | — | — | — | −676.0% | −182.2% | −682.4% | −131.2% | −227.2% | −293.2% | −108.1% |
| Income quality (OCF / net income) | — | — | — | −2.62 | — | — | — | — | −5.96 | — |
| Financial health | ||||||||||
| Total debt | $4.6M | $4.6M | $5.4M | $9.5M | $16.7M | $27.4M | $23.2M | $19.3M | $19.1M | $18.4M |
| Cash & short-term investments | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M | $40.0M | $12.4M | $30.6M | $80.8M | $54.5M |
| Net debt | −$17.0M | −$4.1M | −$11.5M | −$13.1M | −$28.3M | −$12.6M | $10.7M | −$11.4M | −$61.7M | −$36.1M |
| Debt / equity | 0.27 | 0.97 | 0.44 | 0.53 | 13.75 | 1.65 | 1.96 | 0.63 | 0.23 | 0.36 |
| Debt / assets | 0.17 | 0.30 | 0.22 | 0.28 | 0.30 | 0.51 | 0.43 | 0.29 | 0.16 | 0.20 |
| Net debt / EBITDA | — | — | — | −1.66 | — | — | — | — | — | — |
| Current ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 | 3.25 | 0.78 | 2.76 | 5.14 | 3.65 |
| Quick ratio | 3.82 | 1.72 | 2.64 | 2.97 | 1.42 | 2.92 | 0.62 | 2.66 | 5.08 | 3.31 |
| Interest coverage | — | — | — | -0.8 | -3.0 | — | — | — | — | — |
| Working capital | $17.0M | $4.5M | $11.8M | $18.7M | $17.8M | $32.7M | −$8.2M | $31.1M | $76.6M | $51.9M |
| Invested capital | $391,000 | $670,000 | $714,000 | $4.9M | −$27.1M | $4.0M | $22.6M | $19.0M | $20.3M | $14.4M |
| Tangible asset value | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M | $16.6M | $7.4M | $25.2M | $76.0M | $36.0M |
| Net current asset value | $13.3M | −$177,000 | $6.4M | $11.2M | −$2.8M | $10.3M | −$11.6M | $11.6M | $60.1M | $30.1M |
| Capital allocation | ||||||||||
| Dividends paid | $1.6M | — | — | $4,000 | $10.2M | $21.2M | $58,000 | — | $0 | $0 |
| Share buybacks (net) | — | — | $10,000 | $4,000 | $0 | $11,000 | $58,000 | $758,000 | $758,000 | $0 |
| Dividend payout ratio | — | — | — | 0.0% | — | — | — | — | 0.0% | — |
| Capex / revenue | — | — | — | 0.9% | 5.8% | 2.0% | 0.5% | 4.2% | 9.6% | 6.9% |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.03 | 0.62 | 0.07 | 0.07 | 0.41 | 0.45 | 0.75 |
| Stock-based compensation / revenue | — | — | — | 57.9% | 13.4% | 29.1% | 4.9% | 9.3% | 33.3% | 10.5% |
| R&D / revenue | — | — | — | 574.2% | 154.5% | 414.3% | 76.4% | 153.4% | 198.0% | 81.0% |
| SG&A / revenue | — | — | — | 445.5% | 119.6% | 323.8% | 50.0% | 122.0% | 235.9% | 106.1% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | 361.2 | 89.6 | 397.7 | 68.9 | 58.2 | 80.0 | 60.7 |
| Days of inventory on hand | — | — | — | 47.5 | 75.6 | 111.7 | 647.0 | 45.8 | 279.3 | 203.5 |
| Days payables outstanding | 2,988.4 | 3,648.4 | 79.8 | 71.0 | 86.9 | 190.4 | 2,018.0 | 309.6 | 650.9 | 155.5 |
| Cash conversion cycle (days) | — | — | — | 337.7 | 78.2 | 319.0 | -1,302.1 | -205.5 | -291.6 | 108.7 |
| Receivables turnover | — | — | — | 1.01 | 4.07 | 0.92 | 5.30 | 6.27 | 4.56 | 6.01 |
| Payables turnover | 0.12 | 0.10 | 4.57 | 5.14 | 4.20 | 1.92 | 0.18 | 1.18 | 0.56 | 2.35 |
| Inventory turnover | — | — | — | 7.69 | 4.83 | 3.27 | 0.56 | 7.97 | 1.31 | 1.79 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.07 | 0.22 | 0.08 | 0.54 | 0.25 | 0.14 | 0.36 |
| Average receivables | — | — | — | $3.1M | $3.0M | $4.7M | $6.1M | $3.7M | $3.2M | $6.1M |
| Average payables | $2.0M | $3.5M | $3.7M | $3.5M | $4.5M | $9.3M | $12.4M | $9.5M | $8.9M | $10.3M |
| Average inventory | — | — | — | $2.3M | $3.9M | $5.5M | $4.0M | $1.4M | $3.8M | $13.5M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.3% | 7.8% | 5.2% | 15.8% |
Computed from APVO's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
APVO valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0 and the forward P/E is 3.9. Aptevo Therapeutics earned a return on equity of −234.6% in fiscal 2025. It ended the year with $4.6 million of debt and $21.6 million in cash and short-term investments, a net cash position of $17.0 million. It returned $1.6 million to shareholders: $1.6 million in dividends and $0 in share buybacks.
See the APVO income statement, the APVO chart for price history, or the APVO stock overview for the latest quote and news.
APVO key metrics FAQ
What is Aptevo Therapeutics's P/E ratio?
Aptevo Therapeutics's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 3.9. At the end of fiscal 2025 it was —.
What is Aptevo Therapeutics's return on equity?
Aptevo Therapeutics's return on equity (ROE) was −234.6% in fiscal 2025: net income of -$26.0 million on average shareholders' equity of $11.1 million.
How much debt does Aptevo Therapeutics have?
Aptevo Therapeutics had total debt of $4.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.27 and more cash than debt.
What is Aptevo Therapeutics's current ratio?
Aptevo Therapeutics's current ratio was 3.82 at the end of fiscal 2025: current assets were 3.82 times current liabilities.